Tag: umbralisib

#VisualAbstract Phase 2 trial shows umbralisib is safe and effective in patients with chronic lymphocytic leukemia who are intolerant to BTK or PI3Kδ inhibitor therapy

byKathleen Lau

June 4, 2021

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

Single-dose CRISPR therapy reduces hereditary angioedema attacks
Once-weekly oral islatravir-lenacapavir is noninferior to daily HIV therapy
Weight loss is associated with improved vascular function in patients with metabolic dysfunction-associated steatotic liver disease

No Result

View All Result